Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 64.36% is 143% above its 5-year average of 26.47%, near the high end of its 5-year range (0.00%–64.36%).
As of the fiscal period ended Tuesday, June 30, 2026. 23.74% above its 12-month average of 52.01%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 64.36%.
DEBT TO ASSETS RATIO
64.36%
DEBT TO ASSETS RATIO AVG TTM
52.01%
DEBT TO ASSETS RATIO AVG 3Y
37.80%
DEBT TO ASSETS RATIO AVG 5Y
26.47%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+23.74%
CURRENT VS 3Y AVG
+70.27%
CURRENT VS 5Y AVG
+143.14%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 592 covered companies
CURRENT VS SECTOR MEDIAN
+64256.38%
vs the sector median at left
CVRx, Inc.
Market Cap
$41.66M
Debt to Assets Ratio
64.36%
TTM Avg
52.01%
3Y Avg
37.80%
5Y Avg
26.47%
Market Cap
$41.81M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$40.28M
Debt to Assets Ratio
0.22%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$43.82M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$38.82M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$38.52M
Debt to Assets Ratio
0.58%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$44.67M
Debt to Assets Ratio
0.08%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$44.95M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CVRx, Inc. (CVRX) | $41.66M | 64.36% | 52.01% | 37.80% | 26.47% |
| Filana Therapeutics, Inc. (FLNA)vs › | $41.81M | 0.00% | N/A | N/A | N/A |
| Metagenomi, Inc. Common Stock (MGX)vs › | $40.28M | 0.22% | N/A | N/A | N/A |
| BioStem Technologies, Inc. (BSEM)vs › | $43.82M | 0.03% | N/A | N/A | N/A |
| Incannex Healthcare Limited (IXHL)vs › | $38.82M | 0.00% | N/A | N/A | N/A |
| Nephros, Inc. (NEPH)vs › | $38.64M | 0.06% | N/A | N/A | N/A |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.52M | 0.58% | N/A | N/A | N/A |
| Nano-X Imaging Ltd. (NNOX)vs › | $44.67M | 0.08% | N/A | N/A | N/A |
| Werewolf Therapeutics, Inc. (HOWL)vs › | $44.95M | 0.00% | N/A | N/A | N/A |
| DarioHealth Corp. (DRIO)vs › | $45.37M | 0.34% | N/A | N/A | N/A |
Debt/Assets
64.4%
Debt/Equity
2.98
Current Ratio
8.04
Interest Coverage
-8.8x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 64.36% |
| 2026-03-31 | 59.56% |
| 2025-12-31 | 48.47% |
| 2025-09-30 | 45.39% |
| 2025-06-30 | 42.27% |
| 2025-03-31 | 38.91% |
| 2024-12-31 | 37.80% |
| 2024-09-30 | 39.51% |
| 2024-06-30 | 31.87% |
| 2024-03-31 | 28.82% |
| 2023-12-31 | 26.57% |
| 2023-09-30 | 14.45% |
| 2023-06-30 | 13.38% |
| 2023-03-31 | 11.82% |
| 2022-12-31 | 5.67% |
| 2022-09-30 | 0.31% |
| 2022-06-30 | 0.34% |
| 2022-03-31 | 0.35% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 10.72% |
| 2021-06-30 | 35.26% |
| 2021-03-31 | 32.10% |
| 2020-12-31 | 29.76% |
